Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Einride Deepens Collaboration with NVIDIA: Adopts NVIDIA Alpamayo for Autonomous Trucks
-
Nexera Technologies: Fort Technology’s Subsidiary Logia USA Signs Exclusive Distribution Agreement to Expand Fuel Maintenance Solutions for Data Centers Across the U.S.
-
Cerro de Pasco Resources Acquires the Remaining Quiulacocha Tailings and Secures Surface Rights, Consolidating 100% of the Tailings
-
Form 8.3 - Ramsdens Holdings Plc
-
TransUnion Unveils Transaction Matching to Help Merchants Recognize More Customers
-
Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto
-
Coppernico Announces Upcoming Investor Conference Schedule Ahead of Phase 2 Drilling at Sombrero
-
INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027
-
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027
-
WISDOMTREE WTI CRUDE OIL 3X DAILY SHORT SECURITIES ISIN: XS2819844387 PROPOSED AMENDMENT TO THE PRINCIPAL AMOUNT OF THE AFFECTED SECURITIES MEETING OF THE ETP SECURITYHOLDERS
-
Austin Roofing Awarded Major Steel Roof Restoration at Parts Canada Corporate Headquarters in London, Ontario
-
Form 8.3 - Brave Bison Group Plc
-
Global Deep-Sea Scientific and Technological Innovation Forces to Gather in Hainan, China
-
Fidelity D & D Bancorp, Inc. Reports Third Quarter 2026 Financial Results
-
Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
-
Labrador Gold Announces Extension of Non-Brokered Private Placement
-
Stifel Reports Third Quarter 2026 Results
-
Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness
-
Sundance Biosciences Announces Presentation of Phase 1 Results for SUN-627, a Brain-Penetrant TYK2 Inhibitor for the Treatment of Multiple Sclerosis (MS)
-
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE
-
Xali Gold Completes FTA Application for Drilling and Outlines Development Team for Pico Machay
-
Winnebago Industries Reports Fourth Quarter and Full Year Fiscal 2026 Results
-
Auddia Announces Completion of LT350 Phase 1 Feasibility Study and Advancement to Phase 2/3 Engineering with Fresh Consulting
-
Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
-
Aya Gold & Silver Files Updated Preliminary Economic Assessment Technical Report for Boumadine Project
-
Elion Therapeutics to Present Turletricin Clinical Data at IDWeek 2026
-
Micron Biomedical Awarded Federal Vaccine Contract to Fight Rotavirus Through The Skin, Without Needles
-
GOWell Energy Technology Reports Operating Subsidiary’s First Half 2026 Financial Results and Provides Corporate Update
-
Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard
-
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
-
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
-
Reborn Coffee Signs Master Product Supply Agreement with Visvita Corporation
-
Sotera Health Announces Third-Quarter 2026 Earnings Release Date
-
Old National Bancorp Reports Record Third Quarter 2026 Results
-
Agility Robotics Expands Pittsburgh Presence to Support Growing Customer Deployments
-
Winnebago Industries Reports Fourth Quarter and Full Year Fiscal 2026 Results
-
PyroGenesis Announces Dubai Subsidiary to Address Growing Opportunities in Middle East and Asian Markets
-
Aeluma Announces Primit Parikh as Strategic Advisor
-
INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar
-
West Ham United F.C. and BrewDog Unveil Boleyn Brew: A Fan-Created Matchday Beer Made by Hammers, for Hammers
-
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
-
OTC Markets Group Names Meighan McGowan Executive Vice President, Corporate Services
-
Arteris to Announce Financial Results for the Third Quarter 2026 on Thursday, November 5, 2026
-
Human Feedback Foundation, with support from RBC, launches the Agentic AI Design Exchange to help Canadian nonprofits design their own AI agents
-
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
-
Kaltura to Announce Financial Results for Third Quarter 2026 on Monday, November 9, 2026
-
Satellos to Participate in Upcoming Investor Conferences
-
Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto
-
Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met
-
Notification of share transactions by Lumen Investments S.à r.l
